Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:17:29.940Z.
Calculation as of: 2026-10-06T20:17:29.940Z.
Quote observation: 2026-10-06T19:59:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d441fe8f086afba93fb8397567d44bfe794a39cd606e17fb54204e4f45075d8b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
MIRA Pharmaceuticals, Inc.
Market Cap
$29.42M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$30.19M
EV/EBITDA Ratio
N/A
TTM Avg
26.23x
3Y Avg
26.23x
5Y Avg
26.23x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MIRA Pharmaceuticals, Inc. (MIRA) | $29.42M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.37M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $29.57M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.74M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $29.04M | N/A | N/A | N/A | N/A |
| Rockwell Medical, Inc. (RMTI)vs › | $30.19M | N/A | 26.23x | 26.23x | 26.23x |
| Seres Therapeutics, Inc. (MCRB)vs › | $28.47M | N/A | N/A | N/A | N/A |
| SCYNEXIS, Inc. (SCYX)vs › | $30.44M | N/A | 0.97x | 0.97x | 0.97x |
| OneMedNet Corporation (ONMD)vs › | $28.31M | N/A | N/A | N/A | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $28.10M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
